Diagnosis

Cardiomyopathy

Progressive disease of heart muscle.

Etiology

Dilated Cardiomyopathy [3by]

Hypertrophic Cardiomyopathy [ttd][icf]

Restrictive Cardiomyopathy [skd]

Epidemiology

Incidence per 100.000 [owa][g41]

Epidemiology chart for Incidence

Prevalence per 100.000 [owa][g41]

Epidemiology chart for Prevalence

Symptoms & findings

Symptoms

Arrhythmia, Crepitations, Cyanosis, Diastolic murmur, Dizziness, Dyspnea, Edema, Fatigue, Heart murmur, Hepatomegaly, Hypertension, Jugular vein distention, Nail clubbing, Orthopnea, Palpitations, Syncope, Systolic murmur, Tachycardia, Tachypnea, Third heart sound, Weakness, Weight gain

Clinical findings

Anemia, Atrial fibrillation, Cardiomegaly, Decreased Ejection Fraction, Elevated Central Venous Pressure, Elevated Jugular Venous Pressure, Hypoxemia, Pulsus paradoxus

Anamneses

Alcohol

Localized findings

Pain
Radiates
Thorax
Onset
Acute (minutes)Subacute (hours)Gradual (days)
Pattern
ConstantIncreasing
Provoked by
Activity
Quality
Pressing
Severity
Moderate (4-7)Severe (8-10)

Approach

Treatment

Treatment goal: Control heart failure symptoms and manage arrhythmias [3by]

  1. Medications:

    • Angiotensin-converting enzyme (ACE) inhibitors

    • Angiotensin II receptor blockers (ARBs)

    • Beta-blockers

    • Aldosterone antagonists

    • Cardiac glycosides

    • Diuretics

    • Nitrates

    • Vasodilators

    • Anticoagulation

  2. Left ventricular assist device (LVAD)

  3. Cardiac resynchronization therapy (biventricular pacing)

  4. Automatic implantable cardioverter-defibrillators (ICD)

  5. Ventricular restoration surgery

  6. Heart transplantation

Differential diagnoses

Amphetamine toxicity, Aortic stenosis, Beriberi, Cardiac tamponade, Cocaine toxicity, Fabry disease, Glycogen storage disease, Heart failure, Hyperthyroidism, Lead toxicity, Myocardial infarction, Myocarditis, Pericarditis, Pulmonary edema


References

[1] http://emedicine.medscape.com/article/152696 (2014-01-23); [Medscape]

[2] http://emedicine.medscape.com/article/152913 (2014-01-23); [Medscape]

[3] Basit H, Alahmadi MH, Rout P, et al. Hypertrophic Cardiomyopathy. [Updated 2024 Jun 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430788/

[4] http://emedicine.medscape.com/article/153062 (2014-01-23); [Medscape]

[5] Andersson et al. Incidence rates of dilated cardiomyopathy in adult first-degree relatives versus matched controls. Int J Cardiol Heart Vasc. 2022 May 30;41:101065.

[6] Lipshultz et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003 Apr 24;348(17):1647-55.

[7] Butzner et al. (2022). Stable Rates of Obstructive Hypertrophic Cardiomyopathy in a Contemporary Era. Frontiers in Cardiovascular Medicine.

[8] Christiansen et al. Age-Specific Trends in Incidence, Mortality, and Comorbidities of Heart Failure in Denmark, 1995 to 2012. Circulation. 2017 Mar 28;135(13):1214-1223.

[9] Ba et al. Global burden of myocarditis and cardiomyopathy in children and prediction for 2035 based on the global burden of disease study 2019. Front Cardiovasc Med. 2023 May 2;10:1173015.

Scroll to top